Saluda’s Evoke SCS Set To Join Competitive US Spine-Stim Market In Late 2022
The Australian company secured $125m in financing to support commercialization of the Evoke SCS system for chronic pain beginning in late 2022. The US FDA approved Evoke SCS for chronic intractable pain of the trunk and/or limbs, the third major FDA approval of an SCS technology this year so far.
Saluda is preparing to market the Evoke SCS system in the US as the only available SCS system that treats chronic pain by instantaneously reading and reacting to the nerves’ response to stimulation.
On 8 March, the Sydney-based company announced the US Food and Drug Administration approved Evoke SCS for the treatment...